

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

NOVO GROUP LTD.
新源控股有限公司*
(Incorporated in Singapore with limited liability)
(Company Registration No. 198902648H)
Hong Kong Stock Code: 1048
Singapore Stock Code: MR8

OVERSEAS REGULATORY ANNOUNCEMENT

This overseas regulatory announcement is a reproduction of the announcement made by Novo Group Ltd. (the “**Company**”) regarding an announcement pursuant to the Listing Manual of the Singapore Exchange Securities Trading Limited. In compliance with Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, which requires a listed issuer to ensure that if securities of the listed issuer are also listed on other stock exchanges, The Stock Exchange of Hong Kong Limited is simultaneously informed of any information released to any of such other stock exchanges and that such information is released to the market in Hong Kong at the same time as it is released on other markets, and please refer to the attached announcement on the next page issued on the Singapore Exchange Securities Trading Limited on 15 October 2012.

By order of the Board
Novo Group Ltd.
Yu Wing Keung, Dicky
Executive Chairman

Hong Kong, 15 October 2012

As at the date of this announcement, the Board comprises three executive Directors, being Mr. Yu Wing Keung, Dicky, Mr. Chow Kin Wa, Mr. Chow Kin San and three independent non-executive Directors, being Mr. Tang Chi Loong, Mr. Foo Teck Leong and Mr. Tse To Chung, Lawrence.

* *For identification purpose only*

NOVO GROUP LTD.

Registration No. 198902648H

Incorporated in the Republic of Singapore

FURTHER CAPITAL INJECTION TO NOVOWELL ETP LIMITED

Unless otherwise defined, all terms used or referred to in this announcement have the meanings assigned to them in Company's announcements dated 15 March 2011 and 28 June 2011 and circular to its shareholders dated 2 September 2011.

The board (the "Board") of directors (the "Directors") of Novo Group Ltd. (the "Company" or together with its subsidiaries, the "Group") wishes to announce that, on 15 October 2012, Novo ETP, Tong Chang and Idowell have entered into a further supplemental joint venture framework agreement ("2nd Supplemental JVA") to amend and vary the terms of the JVA and the Supplemental JVA whereby Novo ETP and Tong Chang agreed to, among others, further contribute to the registered share capital of Novowell ETP, being a 95% owned subsidiary established in the People's Republic of China to undertake manufacturing and marketing of electrolytic tin plate products, on a pro-rata basis of US\$3,800,000 and US\$200,000, respectively, in order to meet the future funding requirements. Thereafter, the total registered capital of Novowell ETP shall increase from US\$13,500,000 to US\$17,500,000 (the "2nd Capital Injection").

As at the date of this announcement and before the execution of the 2nd Supplemental JVA, Novowell ETP's total registered capital of US\$13,500,000 had been fully paid up.

The Group's share of the 2nd Capital Injection of US\$3,800,000 is to be funded through internal resources and is not expected to have any significant impact on the financial position of the Company for the current financial year ending 30 April 2013.

The Group's equity interest in Novowell ETP shall remain at 95% upon the completion of the 2nd Capital Injection.

Save as the above disclosure, none of the Directors and/or controlling shareholders of the Company has any interest, direct or indirect (other than through their shareholdings in the Company), in the said transaction.

BY ORDER OF THE BOARD

Yu Wing Keung, Dicky
Executive Chairman
15 October 2012